The Urgent Need for Precision Medicine in Cancer and Its Microenvironment: The Paradigmatic Case of Multiple Myeloma

doi:10.3390/jcm11185461

Editorial

. 2022 Sep 16;11(18):5461.

doi: 10.3390/jcm11185461.

The Urgent Need for Precision Medicine in Cancer and Its Microenvironment: The Paradigmatic Case of Multiple Myeloma

Antonio Giovanni Solimando¹, Markus Krebs^{2

3}, Max Bittrich⁴, Hermann Einsele⁴

Affiliations

¹ Guido Baccelli Unit of Internal Medicine, Department of Biomedical Sciences and Human Oncology, School of Medicine, Aldo Moro University of Bari, 70124 Bari, Italy.
² Department of Urology and Pediatric Urology, University Hospital Würzburg, 97080 Würzburg, Germany.
³ Comprehensive Cancer Center Mainfranken, University Hospital Würzburg, 97080 Würzburg, Germany.
⁴ Department of Internal Medicine II, University Hospital Würzburg, Josef-Schneider Straße 2, 97080 Würzburg, Germany.

PMID: 36143110
PMCID: PMC9502417
DOI: 10.3390/jcm11185461

Editorial

The Urgent Need for Precision Medicine in Cancer and Its Microenvironment: The Paradigmatic Case of Multiple Myeloma

Antonio Giovanni Solimando et al. J Clin Med. 2022.

. 2022 Sep 16;11(18):5461.

doi: 10.3390/jcm11185461.

Authors

Antonio Giovanni Solimando¹, Markus Krebs^{2

3}, Max Bittrich⁴, Hermann Einsele⁴

Affiliations

¹ Guido Baccelli Unit of Internal Medicine, Department of Biomedical Sciences and Human Oncology, School of Medicine, Aldo Moro University of Bari, 70124 Bari, Italy.
² Department of Urology and Pediatric Urology, University Hospital Würzburg, 97080 Würzburg, Germany.
³ Comprehensive Cancer Center Mainfranken, University Hospital Würzburg, 97080 Würzburg, Germany.
⁴ Department of Internal Medicine II, University Hospital Würzburg, Josef-Schneider Straße 2, 97080 Würzburg, Germany.

PMID: 36143110
PMCID: PMC9502417
DOI: 10.3390/jcm11185461

Abstract

Precision medicine is particularly relevant for cancer and microenvironment deconvolution for therapeutic purposes in hematological and non-hematological malignancies [...].

PubMed Disclaimer

Conflict of interest statement

The author declares no conflicts of interest.

Cited by

Targeting of mitochondrial fission through natural flavanones elicits anti-myeloma activity.
Torcasio R, Gallo Cantafio ME, Veneziano C, De Marco C, Ganino L, Valentino I, Occhiuzzi MA, Perrotta ID, Mancuso T, Conforti F, Rizzuti B, Martino EA, Gentile M, Neri A, Viglietto G, Grande F, Amodio N. Torcasio R, et al. J Transl Med. 2024 Feb 27;22(1):208. doi: 10.1186/s12967-024-05013-0. J Transl Med. 2024. PMID: 38413989 Free PMC article.
Breaking through Multiple Myeloma: A Paradigm for a Comprehensive Tumor Ecosystem Targeting.
Solimando AG, Krebs M, Desantis V, Marziliano D, Caradonna IC, Morizio A, Argentiero A, Shahini E, Bittrich M. Solimando AG, et al. Biomedicines. 2023 Jul 24;11(7):2087. doi: 10.3390/biomedicines11072087. Biomedicines. 2023. PMID: 37509726 Free PMC article. Review.

References

1. Bolkun L., Tynecka M., Wasiluk T., Piszcz J., Starosz A., Grubczak K., Moniuszko M., Eljaszewicz A. A Proliferation-Inducing Ligand and B-Cell Activating Factor Are Upregulated in Patients with Essential Thrombocythemia. JCM. 2022;11:4663. doi: 10.3390/jcm11164663. - DOI - PMC - PubMed
1. Rasche L., Hudecek M., Einsele H. What Is the Future of Immunotherapy in Multiple Myeloma? Blood. 2020;136:2491–2497. doi: 10.1182/blood.2019004176. - DOI - PubMed
1. Clara J.A., Monge C., Yang Y., Takebe N. Targeting Signalling Pathways and the Immune Microenvironment of Cancer Stem Cells—A Clinical Update. Nat. Rev. Clin. Oncol. 2020;17:204–232. doi: 10.1038/s41571-019-0293-2. - DOI - PubMed
1. Argentiero A., Solimando A.G., Krebs M., Leone P., Susca N., Brunetti O., Racanelli V., Vacca A., Silvestris N. Anti-Angiogenesis and Immunotherapy: Novel Paradigms to Envision Tailored Approaches in Renal Cell-Carcinoma. J. Clin. Med. 2020;9:594. doi: 10.3390/jcm9051594. - DOI - PMC - PubMed
1. Dutta A.K., Alberge J.-B., Sklavenitis-Pistofidis R., Lightbody E.D., Getz G., Ghobrial I.M. Single-Cell Profiling of Tumour Evolution in Multiple Myeloma—Opportunities for Precision Medicine. Nat. Rev. Clin. Oncol. 2022;19:223–236. doi: 10.1038/s41571-021-00593-y. - DOI - PubMed

Publication types

Actions

LinkOut - more resources

Full Text Sources

[1] Bolkun L., Tynecka M., Wasiluk T., Piszcz J., Starosz A., Grubczak K., Moniuszko M., Eljaszewicz A. A Proliferation-Inducing Ligand and B-Cell Activating Factor Are Upregulated in Patients with Essential Thrombocythemia. JCM. 2022;11:4663. doi: 10.3390/jcm11164663. - DOI - PMC - PubMed

[2] Bolkun L., Tynecka M., Wasiluk T., Piszcz J., Starosz A., Grubczak K., Moniuszko M., Eljaszewicz A. A Proliferation-Inducing Ligand and B-Cell Activating Factor Are Upregulated in Patients with Essential Thrombocythemia. JCM. 2022;11:4663. doi: 10.3390/jcm11164663. - DOI - PMC - PubMed

[3] Rasche L., Hudecek M., Einsele H. What Is the Future of Immunotherapy in Multiple Myeloma? Blood. 2020;136:2491–2497. doi: 10.1182/blood.2019004176. - DOI - PubMed

[4] Rasche L., Hudecek M., Einsele H. What Is the Future of Immunotherapy in Multiple Myeloma? Blood. 2020;136:2491–2497. doi: 10.1182/blood.2019004176. - DOI - PubMed

[5] Clara J.A., Monge C., Yang Y., Takebe N. Targeting Signalling Pathways and the Immune Microenvironment of Cancer Stem Cells—A Clinical Update. Nat. Rev. Clin. Oncol. 2020;17:204–232. doi: 10.1038/s41571-019-0293-2. - DOI - PubMed

[6] Clara J.A., Monge C., Yang Y., Takebe N. Targeting Signalling Pathways and the Immune Microenvironment of Cancer Stem Cells—A Clinical Update. Nat. Rev. Clin. Oncol. 2020;17:204–232. doi: 10.1038/s41571-019-0293-2. - DOI - PubMed

[7] Argentiero A., Solimando A.G., Krebs M., Leone P., Susca N., Brunetti O., Racanelli V., Vacca A., Silvestris N. Anti-Angiogenesis and Immunotherapy: Novel Paradigms to Envision Tailored Approaches in Renal Cell-Carcinoma. J. Clin. Med. 2020;9:594. doi: 10.3390/jcm9051594. - DOI - PMC - PubMed

[8] Argentiero A., Solimando A.G., Krebs M., Leone P., Susca N., Brunetti O., Racanelli V., Vacca A., Silvestris N. Anti-Angiogenesis and Immunotherapy: Novel Paradigms to Envision Tailored Approaches in Renal Cell-Carcinoma. J. Clin. Med. 2020;9:594. doi: 10.3390/jcm9051594. - DOI - PMC - PubMed

[9] Dutta A.K., Alberge J.-B., Sklavenitis-Pistofidis R., Lightbody E.D., Getz G., Ghobrial I.M. Single-Cell Profiling of Tumour Evolution in Multiple Myeloma—Opportunities for Precision Medicine. Nat. Rev. Clin. Oncol. 2022;19:223–236. doi: 10.1038/s41571-021-00593-y. - DOI - PubMed

[10] Dutta A.K., Alberge J.-B., Sklavenitis-Pistofidis R., Lightbody E.D., Getz G., Ghobrial I.M. Single-Cell Profiling of Tumour Evolution in Multiple Myeloma—Opportunities for Precision Medicine. Nat. Rev. Clin. Oncol. 2022;19:223–236. doi: 10.1038/s41571-021-00593-y. - DOI - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

The Urgent Need for Precision Medicine in Cancer and Its Microenvironment: The Paradigmatic Case of Multiple Myeloma

Affiliations

The Urgent Need for Precision Medicine in Cancer and Its Microenvironment: The Paradigmatic Case of Multiple Myeloma

Authors

Affiliations

Abstract

Conflict of interest statement

Similar articles

Cited by

References

Publication types

LinkOut - more resources

Full Text Sources

Abstract

Conflict of interest statement

Similar articles

Cited by

References

Publication types

Related information

LinkOut - more resources

Full Text Sources